MRK Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Merck & (NYSE: MRK)
›
Merck & (NYSE: MRK) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 73,000 employees.
The shares were at 132.73 USD on 19 November 2026, up 45.1% over 52 weeks. Its 52-week range is 92.11 USD to 156.92 USD: the price is 15.4% below the high and 44.1% above the low.
At a market capitalisation of 327.41B USD, it trades at 134.2 times trailing earnings and 14.8 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 25.4, a premium of 427% for MRK. It pays a dividend yielding 2.55%, against a median of 2.43% among the dividend payers in that peer group.
Merck & reports return on equity of 34.7%, an operating margin of 35.2% and revenue up 4.7% year over year.
Its debt exceeds its cash by 44.25B USD, a debt-to-equity ratio of 0.94. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 26 analysts cover the stock, with an average rating of Buy; their mean price target of 161.53 USD is 21.7% above the current price. The next earnings report is expected on 2 February 2027.